Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ascendis Pharma A/S (ASND) vs iShares 1 3 Year Treasury Bond ETF (SHY) Price & Performance

Ascendis Pharma A/STrade
iShares 1 3 Year Treasury Bond ETFTrade

Price performance (Past 24H)

Key statistics

Ascendis Pharma A/S vs iShares 1 3 Year Treasury Bond ETF — how do they compare? Ascendis Pharma A/S trades at $254.76 (market cap $16.67B), while iShares 1 3 Year Treasury Bond ETF trades at $81.95. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, iShares 1 3 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.

ASNDSHY
Market Cap
$16.67B
Sector
HealthFixed Income
52-Week High
$277.18$83.18
52-Week Low
$189.74$81.77
Enterprise Value
$17.04B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ascendis Pharma A/S

Ascendis Pharma (ASND) trades at $255.50, showing minimal daily movement with a slight decline of 0.05%. The stock maintains a bullish technical outlook with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates impressive revenue growth from $51M in 2022 to $720M in 2025, though it remains unprofitable with a net loss of $228M. Analyst sentiment is overwhelmingly positive with 92% buy ratings and a $309.75 consensus price target representing 21% upside potential.

ASND presents a compelling growth story with multiple product launches driving revenue expansion, but carries significant execution risk as the company transitions to profitability. The negative shareholder equity and high debt levels require careful monitoring, though positive cash flow generation in 2025 marks an important inflection point. The stock's premium valuation reflects expectations for continued growth in its rare endocrine franchise.

iShares 1 3 Year Treasury Bond ETF

SHY, the iShares 1-3 Year Treasury Bond ETF, trades at $81.955, up 0.12% on the day, with a bearish technical signal driven by moving averages. Recent news highlights institutional accumulation, including Barry Investment Advisors increasing its stake by 48.1% in Q2 2026 (SEC filing, August 10, 2026), amid fluctuating Treasury yields influenced by inflation data and Middle East tensions. The ETF maintains a steady dividend schedule, with recent payouts of $0.24-$0.25 per share.

Outlook remains cautious due to interest rate uncertainty and inflation pressures, offering income stability but limited growth. Risks include Fed policy shifts and oil-price volatility, while institutional buying signals defensive positioning. The neutral oscillator reading suggests short-term consolidation near current levels.

Returns comparison

Trailing returns across standard periods

About Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.

Read more on ASND

About iShares 1 3 Year Treasury Bond ETF

SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.

Read more on SHY